October 29, 2020 -- Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.
This announcement follows the establishment of Takeda's manufacturing capabilities to produce Novavax' COVID-19 vaccine candidate in its Japan-based facilities. Takeda's efforts to bring Moderna's and Novavax' COVID-19 vaccine candidates to Japan are supported by the Ministry of Health, Labour, and Welfare and the Japan Agency for Medical Research and Development.
Under the terms of the agreement, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing the 50 million doses in Japan. Moderna will provide the finished product and will support Takeda with its development and regulatory efforts.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
